Tolerability and pharmacokinetics of oxaloacetate 100 mg capsules in Alzheimer's subjects

BBA Clinical

Volumn 5, Issue , 2016, Pages 120-123

  Swerdlow, Russell H ^a,b   Bothwell, Rebecca ^a   Hutfles, Lewis ^a   Burns, Jeffrey M ^a,b   Reed, Gregory A ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Clinical trial; Mitochondria; Oxaloacetate; Pharmacokinetics

Indexed keywords

ASCORBIC ACID; OXALOACETIC ACID;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BIOENERGY; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING SCALE; DRUG TOLERABILITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; VERY ELDERLY;

EID: 84961245541     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2016.03.005     Document Type: Article

References (18)

1. Swerdlow R.H. Pathogenesis of Alzheimer's disease. Clin. Interv. Aging 2007, 2:347-359.
2. Swerdlow R.H. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid. Redox Signal. 2012, 16:1434-1455.
3. de Leon M.J., Ferris S.H., George A.E., Christman D.R., Fowler J.S., Gentes C., Reisberg B., Gee B., Emmerich M., Yonekura Y., Brodie J., Wolf Kricheff A.P. Positron emission tomographic studies of aging and Alzheimer disease, AJNR. Am. J. Neuroradiol. 1983, 4:568-571.
4. Foster N.L., Chase T.N., Fedio P., Patronas N.J., Brooks R.A., Di Chiro G. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 1983, 33:961-965.
5. Friedland R.P., Budinger T.F., Ganz E., Yano Y., Mathis C.A., Koss B., Ober B.A., Huesman R.H., Derenzo S.E. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J. Comput. Assist. Tomogr. 1983, 7:590-598.
6. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., Harris P.L., Jones P.K., Petersen R.B., Perry G., Smith M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 2001, 21:3017-3023.
7. Sheng B., Wang X., Su B., Lee H.G., Casadesus G., Perry G., Zhu X. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J. Neurochem. 2012, 120:419-429.
8. Swerdlow R.H. Bioenergetic medicine. Br. J. Pharmacol. 2014, 171:1854-1869.
9. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim. Biophys. Acta 2014, 1842:1219-1231.
10. Wilkins H.M., Koppel S., Carl S.M., Ramanujan S., Weidling I., Michaelis M.L., Michaelis E.K., Swerdlow R.H. Oxaloacetate enhances neuronal cell bioenergetic fluxes and infrastructure. J. Neurochem. 2016, (in press).
11. Wilkins H.M., Harris J.L., Carl S.M., L.E, Lu J., Selfridge J.Eva, Roy N., Hutfles L., Koppel S., Morris J., Burns J.M., Michaelis M.L., Michaelis E.K., Brooks W.M., Swerdlow R.H. Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis. Hum. Mol. Genet. 2014, 23:6528-6541.
12. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
13. Tan B., Lu Z., Dong S., Zhao G., Kuo M.S. Derivatization of the tricarboxylic acid intermediates with O-benzylhydroxylamine for liquid chromatography-tandem mass spectrometry detection. Anal. Biochem. 2014, 465:134-147.
14. Yoshikawa K. Studies on the anti-diabetic effect of sodium oxaloacetate. Tohoku J. Exp. Med. 1968, 96:127-141.
15. Campos F., Sobrino T., Ramos-Cabrer P., Castillo J. Oxaloacetate: a novel neuroprotective for acute ischemic stroke. Int. J. Biochem. Cell Biol. 2012, 44:262-265.
16. Ruban A., Berkutzki T., Cooper I., Mohar B., Teichberg V.I. Blood glutamate scavengers prolong the survival of ats and ice with rain-mplanted gliomas. Investig. New Drugs 2012.
17. Zlotnik A., Sinelnikov I., Gruenbaum B.F., Gruenbaum S.E., Dubilet M., Dubilet E., Leibowitz A., Ohayon S., Regev A., Boyko M., Shapira Y., Teichberg V.I. Effect of glutamate and blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome and pathohistology of the hippocampus after traumatic brain injury in rats. Anesthesiology 2012, 116:73-83.
18. Ruban A., Malina K.C., Cooper I., Graubardt N., Babakin L., Jona G., Teichberg V.I. Combined treatment of an amyotrophic lateral sclerosis rat model with recombinant GOT1 and oxaloacetic acid: a novel neuroprotective treatment. Neurodegener Dis. 2015, 15:233-242.